Nebenwirkungen · Eucreas
Eucreas 50 mg/850 mg film-coated tablets Eucreas 50 mg/1000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 8
HOS-209045 · Präparat HOS-154229
Adverse reactions reported in patients who received vildagliptin in double-blind clinical trials as monotherapy and add-on therapies are listed below by system organ class and absolute frequency. Frequencies are defined as very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1 000 to <1/100); rare (≥1/10 000 to <1/1 000); very rare (<1/10 000), not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-08T16:29:00Z · SHA-256 897fac054670da78d771c98441df8c405a2e3199c8f841ecd467d8e23dfc00ad · Passage d8e3ee445f9adf4f38f0a959d86a827bfdd5bcb91d4fdb5338b4204c6e7cf148 · Zeichen 937–1447 im Abschnitt